Modulation of cancer-associated fibroblasts by nanodelivery system to enhance efficacy of tumor therapy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Guo J, Zeng H, Chen Y. Emerging nano drug delivery systems targeting cancer-associated fibroblasts for improved antitumor effect and tumor drug penetration. Mol. Pharm. 17(4), 1028–1048 (2020). •• Describes the biological mechanisms by which cancer-associated fibroblasts (CAFs) interfere with nanotherapies and the strategies associated with nanodelivery systems targeting CAFs. Guiding implications are provided for the current research.
  Medline CASGoogle Scholar
• 2. Belli C, Trapani D, Viale G et al. Targeting the microenvironment in solid tumors. Cancer Treat. Rev. 65, 22–32 (2018). • Describes the characteristics of the tumor microenvironment and the interconnection between CAFs and tumors. It describes theoretical aspects that assist the current research.
  Medline CASGoogle Scholar
• 3. Du Y, Cao M, Liu Y et al. Tumor microenvironment remodeling modulates macrophage phenotype in breast cancer lymphangiogenesis. FASEB J. 36(4), e22248 (2022).
  Medline CASGoogle Scholar
• 4. Lawrie TA, Rabbie R, Thoma C. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer. Cochrane Database Syst. Rev. 10, London, UK (2013).
  Google Scholar
• 5. Fernandes C, Suares D, Yergeri MC. Tumor microenvironment targeted nanotherapy. Front. Pharmacol. 9, doi:10.3389/fphar.2018.01230 (2018).
  Google Scholar
• 6. Yang M, Li J, Gu P et al. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact. Mater. 6(7), 1973–1987 (2021).
  Medline CASGoogle Scholar
• 7. Batra H, Pawar S, Bahl D. Curcumin in combination with anti-cancer drugs: a nanomedicine review. Pharmacol. Res. 139, 91–105 (2019).
  Medline CASGoogle Scholar
• 8. Colombo M, Rizzuto MA, Pacini C et al. Half-chain cetuximab nanoconjugates allow multitarget therapy of triple negative breast cancer. Bioconjug. Chem. 29(11), 3817–3832 (2018).
  Medline CASGoogle Scholar
• 9. Saw PE, Chen J, Song E. Targeting CAFs to overcome anticancer therapeutic resistance. Trends Cancer 8(7), 527–555 (2022).
  Medline CASGoogle Scholar
• 10. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am. J. Cancer Res. 1(4), 482 (2011).
  Medline CASGoogle Scholar
• 11. Hinz B, Phan SH, Thannickal VJ et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am. J. Pathol. 180(4), 1340–1355 (2012).
  Medline CASGoogle Scholar
• 12. Kalluri R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16(9), 582–598 (2016).
  Medline CASGoogle Scholar
• 13. Augsten M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front. Oncol. 4, 62 (2014).
  MedlineGoogle Scholar
• 14. Shiga K, Hara M, Nagasaki T et al. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers 7(4), 2443–2458 (2015).
  MedlineGoogle Scholar
• 15. Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 30(9), 1002–1019 (2016).
  Medline CASGoogle Scholar
• 16. Erez N, Truitt M, Olson P et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner. Cancer Cell 17(2), 135–147 (2010).
  Medline CASGoogle Scholar
• 17. Kraman M, Bambrough PJ, Arnold JN et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein–α. Science 330(6005), 827–830 (2010).
  Medline CASGoogle Scholar
• 18. Sahai E, Astsaturov I, Cukierman E et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20(3), 174–186 (2020).
  Medline CASGoogle Scholar
• 19. Hay ED. An overview of epithelio-mesenchymal transformation. Cells Tissues Organs 154(1), 8–20 (1995).
  CASGoogle Scholar
• 20. Forino M, Torregrossa R, Ceol M et al. TGFβ1 induces epithelial–mesenchymal transition, but not myofibroblast transdifferentiation of human kidney tubular epithelial cells in primary culture. Int. J. Exp. Pathol. 87(3), 197–208 (2006).
  Medline CASGoogle Scholar
• 21. Direkze NC, Hodivala-Dilke K, Jeffery R et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 64(23), 8492–8495 (2004).
  Medline CASGoogle Scholar
• 22. Mishra PJ, Mishra PJ, Humeniuk R et al. Carcinoma-associated fibroblast–like differentiation of human mesenchymal stem cells. Cancer Res. 68(11), 4331–4339 (2008).
  Medline CASGoogle Scholar
• 23. Yeon JH, Jeong HE, Seo H et al. Cancer-derived exosomes trigger endothelial to mesenchymal transition followed by the induction of cancer-associated fibroblasts. Acta Biomater. 76, 146–153 (2018).
  Medline CASGoogle Scholar
• 24. Zeisberg EM, Potenta S, Xie L et al. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 67(21), 10123–10128 (2007).
  Medline CASGoogle Scholar
• 25. He Q, Guo S, Qian Z et al. Development of individualized anti-metastasis strategies by engineering nanomedicines. Chem. Soc. Rev. 44(17), 6258–6286 (2015).
  Medline CASGoogle Scholar
• 26. Chang C-H, Qiu J, O'Sullivan D et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162(6), 1229–1241 (2015).
  Medline CASGoogle Scholar
• 27. Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J. Nucl. Med. 62(2), 160–167 (2021).
  Medline CASGoogle Scholar
• 28. Fearon DT. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol. Res. 2(3), 187–193 (2014).
  Medline CASGoogle Scholar
• 29. Yang X, Lin Y, Shi Y et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3–CCL2 signaling. Cancer Res. 76(14), 4124–4135 (2016).
  Medline CASGoogle Scholar
• 30. Cheng JD, Dunbrack RL Jr, Valianou M et al. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 62(16), 4767–4772 (2002).
  Medline CASGoogle Scholar
• 31. Cherng S, Young J, Ma H. Alpha-smooth muscle actin (α-SMA). J. Am. Sci. 4(4), 7–9 (2008).
  Google Scholar
• 32. Özdemir BC, Pentcheva-Hoang T, Carstens JL et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25(6), 719–734 (2014).
  Medline CASGoogle Scholar
• 33. Yin L, Tang Y, Yuan Y. An overview of the advances in research on the molecular function and specific role of circular RNA in cardiovascular diseases. BioMed Res. Int. 2022, 1–10 (2022).
  CASGoogle Scholar
• 34. Becker LM, O'Connell JT, Vo AP et al. Epigenetic reprogramming of cancer-associated fibroblasts deregulates glucose metabolism and facilitates progression of breast cancer. Cell Rep. 31(9), doi:10.1016/j.celrep.2020.107701 (2020).
  Google Scholar
• 35. Wang Z, Li W, Guo Q et al. Insulin-like growth factor-1 signaling in lung development and inflammatory lung diseases. BioMed Res. Int. 2018, doi:10.1155/2018/6057589 (2018).
  Google Scholar
• 36. Lelièvre P, Sancey L, Coll J-L et al. Iron dysregulation in human cancer: altered metabolism, biomarkers for diagnosis, prognosis, monitoring and rationale for therapy. Cancers 12(12), 3524 (2020).
  Medline CASGoogle Scholar
• 37. Long X, Xiong W, Zeng X et al. Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1/ERβ/Bcl-2 signalling. Cell Death Dis. 10(5), 1–16 (2019).
  Google Scholar
• 38. Yi Y, Zeng S, Wang Z et al. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small-cell lung cancers via HGF/IGF-1/ANXA2 signaling. Biochim. Biophys. Acta Mol. Basis Dis. 1864(3), 793–803 (2018).
  Medline CASGoogle Scholar
• 39. Fassnacht M, Berruti A, Baudin E et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 16(4), 426–435 (2015).
  Medline CASGoogle Scholar
• 40. Kazlauskas A. PDGFs and their receptors. Gene 614, 1–7 (2017).
  Medline CASGoogle Scholar
• 41. Mai W, Chen M, Huang M et al. Targeting platelet-derived growth factor receptor β inhibits the proliferation and motility of human pterygial fibroblasts. Expert Opin. Ther. Targets 23(9), 805–817 (2019).
  Medline CASGoogle Scholar
• 42. Primac I, Maquoi E, Blacher S et al. Stromal integrin α11 regulates PDGFRβ signaling and promotes breast cancer progression. J. Clin. Invest. 129(11), 4609–4628 (2019).
  Medline CASGoogle Scholar
• 43. Suzuki J, Aokage K, Neri S et al. Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. Lung Cancer 153, 1–10 (2021).
  Medline CASGoogle Scholar
• 44. Takiguchi K, Shoda K, Nakayama T et al. Soluble podoplanin as a biomarker in diffuse-type gastric cancer. Oncol. Rep. 47(3), 1–7 (2022).
  MedlineGoogle Scholar
• 45. Suzuki H, Kaneko MK, Kato Y. Roles of podoplanin in malignant progression of tumor. Cells 11(3), 575 (2022).
  Medline CASGoogle Scholar
• 46. Jenkins BH, Buckingham JF, Hanley CJ et al. Targeting cancer-associated fibroblasts: challenges, opportunities and future directions. Pharmacol. Ther. 240, doi:10.1016/j.pharmthera.2022.108231 (2022).
  MedlineGoogle Scholar
• 47. Gilardi L, Airò Farulla LS, Demirci E et al. Imaging cancer-associated fibroblasts (CAFs) with FAPi PET. Biomedicines 10(3), 523 (2022).
  Medline CASGoogle Scholar
• 48. Ji T, Zhao Y, Ding Y et al. Transformable peptide nanocarriers for expeditious drug release and effective cancer therapy via cancer-associated fibroblast activation. Angew. Chem. Int. Ed. 55(3), 1050–1055 (2016).
  Medline CASGoogle Scholar
• 49. Lang J, Zhao X, Qi Y et al. Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem. ACS Nano 13(11), 12357–12371 (2019).
  Medline CASGoogle Scholar
• 50. Yu Q, Qiu Y, Li J et al. Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor therapy. J. Control. Rel. 321, 564–575 (2020).
  Medline CASGoogle Scholar
• 51. Zheng S, Wang J, Ding N et al. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer. Nanobiotechnology 19(1), 1–18 (2021).
  Google Scholar
• 52. Kong FH, Ye QF, Miao XY et al. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics 11(11), 5464 (2021).
  Medline CASGoogle Scholar
• 53. Piersma B, Hayward M-K, Weaver VM. Fibrosis and cancer: a strained relationship. Biochim. Biophys. Acta Rev. Cancer 1873(2), doi:10.1016/j.bbcan.2020.188356 (2020).
  MedlineGoogle Scholar
• 54. Evanko SP, Potter-Perigo S, Bollyky PL et al. Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol. 31(2), 90–100 (2012).
  Medline CASGoogle Scholar
• 55. Knops AM, South A, Rodeck U et al. Cancer-associated fibroblast density, prognostic characteristics, and recurrence in head and neck squamous cell carcinoma: a meta-analysis. Front. Oncol. 10, doi:10.3389/fonc.2020.565306 (2020).
  MedlineGoogle Scholar
• 56. Jacobetz MA, Chan DS, Neesse A et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62(1), 112–120 (2013).
  Medline CASGoogle Scholar
• 57. Lokeshwar VB, Mirza S, Jordan A. Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv. Cancer Res. 123, 35–65 (2014).
  Medline CASGoogle Scholar
• 58. Sato N, Cheng X-B, Kohi S et al. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma. Acta Pharm. Sin. B 6(2), 101–105 (2016).
  MedlineGoogle Scholar
• 59. Yu X, Su Q, Chang X et al. Multimodal obstruction of tumorigenic energy supply via bionic nanocarriers for effective tumor therapy. Biomaterials 278, doi:10.1016/j.biomaterials.2021.121181 (2021).
  Google Scholar
• 60. Zuo T, Zhang J, Yang J et al. On-demand responsive nanoplatform mediated targeting of CAFs and down-regulating mtROS-PYK2 signaling for antitumor metastasis. Biomater. Sci. 9(5), 1872–1885 (2021).
  Medline CASGoogle Scholar
• 61. Zhang Y, Zhou J, Chen X et al. Modulating tumor-stromal crosstalk via a redox-responsive nanomedicine for combination tumor therapy. J. Control. Rel. 356, 525–541 (2023).
  Medline CASGoogle Scholar
• 62. Zhu Y, Wen L, Shao S et al. Inhibition of tumor-promoting stroma to enforce subsequently targeting AT1R on tumor cells by pathological inspired micelles. Biomaterials 161, 33–46 (2018).
  Medline CASGoogle Scholar
• 63. Farhood B, Najafi M, Mortezaee K. Cancer-associated fibroblasts: secretions, interactions, and therapy. J. Cell. Biochem. 120(3), 2791–2800 (2019).
  Medline CASGoogle Scholar
• 64. Fu R, Zhang Y, Li H et al. LW106, a novel inhibitor of IDO1, suppresses tumor progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in the tumor microenvironment. Br. J. Pharmacol. 175, 3034–3049 (2018).
  Medline CASGoogle Scholar
• 65. Panagi M, Voutouri C, Mpekris F et al. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. Theranostics 10(4), 1910 (2020).
  Medline CASGoogle Scholar
• 66. Mardhian DF, Storm G, Bansal R et al. Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo. J. Control. Rel. 290, 1–10 (2018).
  Medline CASGoogle Scholar
• 67. Xia J, Zhang S, Zhang R et al. Targeting therapy and tumor microenvironment remodeling of triple-negative breast cancer by ginsenoside Rg3 based liposomes. J. Nanobiotechnol. 20(1), 1–22 (2022).
  MedlineGoogle Scholar
• 68. Teixeira AF, Ten Dijke P, Zhu H-J. On-target anti-TGF-β therapies are not succeeding in clinical cancer treatments: what are remaining challenges? Front. Cell Dev. Biol. 8, 605 (2020).
  MedlineGoogle Scholar
• 69. Higashino N, Koma Y-I, Hosono M et al. Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma. Lab. Invest. 99(6), 777–792 (2019).
  Medline CASGoogle Scholar
• 70. Wan Z, Huang H, West RE III et al. Overcoming pancreatic cancer immune resistance by codelivery of CCR2 antagonist using a STING-activating gemcitabine-based nanocarrier. Mater. Today 62, 33–50 (2022).
  Google Scholar
• 71. Ullah A, Chen G, Yibang Z et al. A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis. Biomater. Sci. 10(10), 2650–2664 (2022). • Describes a new approach based on CXCR4-targeted combinatorial liposomes for the treatment of liver fibrosis, providing a summary of advanced nanosystems to modulate CAFs and treat tumors.
  Medline CASGoogle Scholar
• 72. Cai H, Dai X, Wang X et al. A nanostrategy for efficient imaging-guided antitumor therapy through a stimuli-responsive branched polymeric prodrug. Adv. Sci. 7(6), doi:10.1002/advs.201903243 (2020).
  Google Scholar
• 73. Ji Y, Liu X, Huang M et al. Development of self-assembled multi-arm polyrotaxanes nanocarriers for systemic plasmid delivery in vivo. Biomaterials 192, 416–428 (2019).
  Medline CASGoogle Scholar
• 74. Chen E, Han S, Song B et al. Mechanism investigation of hyaluronidase-combined multistage nanoparticles for solid tumor penetration and antitumor effect. Int. J. Nanomed. 15, 6311–6324 (2020).
  Medline CASGoogle Scholar
• 75. Afshari AR, Sanati M, Mollazadeh H et al. Nanoparticle-based drug delivery systems in cancer: a focus on inflammatory pathways. Semin. Cancer Biol. 86(2), 860–872 (2022).
  Medline CASGoogle Scholar
• 76. Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat. Rev. Clin. Oncol. 18(12), 792–804 (2021).
  Medline CASGoogle Scholar
• 77. Bai J, Liu T, Tu B et al. Autophagy loss impedes cancer-associated fibroblast activation via downregulating proline biosynthesis. Autophagy 19(2), 632–643 (2022).
  MedlineGoogle Scholar
• 78. Zhen Z, Tang W, Wang M et al. Protein nanocage mediated fibroblast-activation protein targeted photoimmunotherapy to enhance cytotoxic T cell infiltration and tumor control. Nano Lett. 17(2), 862–869 (2017).
  Medline CASGoogle Scholar
• 79. Klymenko Y, Nephew KP. Epigenetic crosstalk between the tumor microenvironment and ovarian cancer cells: a therapeutic road less traveled. Cancers 10(9), 295 (2018).
  MedlineGoogle Scholar
• 80. Tan P, Chen X, Zhang H et al. Artificial intelligence aids in development of nanomedicines for cancer management. Semin. Cancer Biol. 89, 61–75 (2023). •• Describes advances in artificially intelligent nanomedicines for cancer management in diagnosis, monitoring and treatment and in the development of precision medicine, providing assistance for future applications in nanosystem modulation of CAFs to improve oncology treatment outcomes.
  Medline CASGoogle Scholar